(Q44268060)

1 December 2017

title

Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma (English)

1 reference

1 December 2017

1 reference

Christoph Tinchon

1

1 reference

1 December 2017

Eva Hubmann

2

1 reference

1 December 2017

Angelika Pichler

3

1 reference

1 December 2017

Felix Keil

4

1 reference

1 December 2017

Martin Pichler

5

1 reference

1 December 2017

Hans Rabl

6

1 reference

1 December 2017

Martin Uggowitzer

7

1 reference

1 December 2017

Kurt Jilek

8

1 reference

1 December 2017

Gerhard Leitner

9

1 reference

1 December 2017

Thomas Bauernhofer

10

1 reference

1 December 2017

publication date

27 February 2013

1 reference

1 December 2017

1 reference

1 December 2017

volume

52

1 reference

1 December 2017

issue

6

1 reference

1 December 2017

page(s)

1231-1233

1 reference

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2013.771821

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2013.771821

A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2013.771821

Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2013.771821

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2013.771821

Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2013.771821

Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2013.771821

Systematic review of outcome of synchronous portal-superior mesenteric vein resection during pancreatectomy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2013.771821

Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2013.771821

Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2013.771821

Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2013.771821

Borderline resectable pancreatic cancer: the importance of this emerging stage of disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2013.771821

Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2013.771821

Downstaging in Pancreatic Cancer: A Matched Analysis of Patients Resected Following Systemic Treatment of Initially Locally Unresectable Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2013.771821

10.3109/0284186X.2013.771821

21 January 2018

Identifiers

DOI

1 reference

1 December 2017

1 reference